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Fritz Mellert, MD,z Georg Nickenig, MD,* Christoph Hammerstingl, MD*ABSTRACTFro
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MaOBJECTIVES The purpose of this study was to investigate the persistence rates of iatrogenic atrial septal defect (iASD)
after interventional edge-to-edge repair with serial transesophageal echocardiography examinations and close clinical
follow-up (FU).
BACKGROUND Transcatheter mitral valve repair (TMVR) with the MitraClip system (Abbott Vascular, Abbott Park,
Illinois) is a therapeutic alternative to surgery in selected high-risk patients. Clip placement requires interatrial trans-
septal puncture and meticulous manipulation of the steerable sheath. The persistence of iASD after MitraClip procedures
and its clinical relevance is unknown.
METHODS A total of 66 patients (76.7% male, mean age 77.1  7.9 years) with symptomatic mitral regurgitation (MR)
at prohibitive surgical risk (EuroSCORE II 10.1  6.1%) underwent MitraClip procedures and completed 6 months of FU.
RESULTS Transesophageal echocardiography after FU showed persistent iASD in 50% of cases. Patients with iASD did
not signiﬁcantly differ from patients without ASD concerning baseline characteristics, New York Heart Association
functional class, severity of MR, and acute procedural success rates (p > 0.05). When comparing procedural details and
hemodynamic measures between groups, MitraClip procedures took longer in patients without iASD (82.4  39.7 min vs.
68.9  45.5 min; p ¼ 0.05), and echocardiography after FU showed less decrease of systolic pulmonary artery pressures
in the iASD group (1.6  14.1 mm Hg vs. 9.3  17.4 mm Hg; p ¼ 0.02). Clinically, patients with iASD presented more
often with New York Heart Association functional classes >II after FU (57% vs. 30%; p ¼ 0.04), showed higher levels of
N-terminal pro-brain natriuretic peptide (6,667.3  7,363.9 ng/dl vs. 4,835.9  6,681.7 ng/dl; p ¼ 0.05), and had less
improvement in 6-min walking distances (20.8  107.4 m vs. 114.6  116.4 m; p ¼ 0.001). Patients with iASD showed
higher death rates during 6 months (16.6% vs. 3.3%; p ¼ 0.05). Cox regression analysis found that only persistence of
iASD (p ¼ 0.04) was associated with 6-month survival.
CONCLUSIONS The persistence rate of 50% iASD after MitraClip procedures is considerably high. Persistent interatrial
shunting was associated with worse clinical outcomes and increased mortality. Further studies are warranted to inves-
tigate if persistent interatrial shunting is the mediator or marker of advanced disease in these patients. (J Am Coll Cardiol
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451AB BR E V I A T I O N S
AND ACRONYM S
DMR = degenerative mitral
regurgitation
FMR = functional mitral
regurgitation
FU = follow-up
iASD = iatrogenic atrial
septal defect
MR = mitral regurgitation
NYHA = New York Heart
Association
TEE = transesophageal
echocardiography
TMVR = transcatheter mitral
valve repair
TTE = transthoracic
echocardiographyT ranscatheter mitral valve repair (TMVR) hasbeen developed as a therapeutic alternativeto mitral valve (MV) surgery for symptomatic
patients with relevant mitral regurgitation (MR)
at prohibitive surgical risk. Interventional edge-
to-edge repair with the MitraClip system (Abbott
Vascular, Abbott Park, Illinois) has proven to be safe
and effective for the reduction of MR in different
patient cohorts with either functional mitral regurgi-
tation (FMR) or degenerative mitral regurgitation
(DMR) valve disease (1,2), and this technique has
been widely adapted for clinical use, with more than
13,000 documented implants worldwide.
In clinical practice, TMVR with the MitraClip is
mainly used to reduce FMR in end-stage heart failure
patients with either dilated or ischemic cardiomyop-
athy (3–6). In this high-risk population, acute proce-
dural success rates of up to 99% with signiﬁcant MR
reduction were reported (7), followed by symptomatic
improvement in approximately 80% of cases.SEE PAGE 460Nevertheless, TMVR with the MitraClip is still an
evolving technique, and factors predicting clinical
outcomes after technically-successful clip implanta-
tion are not well deﬁned. Cardiologists are facing a
complex procedure, and clip placement requires
venous groin access, interatrial transseptal punc-
ture, and advancement of a 21-F (7.2 mm) steerable
sheath into the left atrium. Despite increasing
knowledge on speciﬁc procedural characteristics
and technical aspects of TMVR, the persistence rate
of iatrogenic atrial septal defects (iASDs) after
MitraClip procedures is unknown. Furthermore, the
effect of iASD on clinical outcomes in patient co-
horts with advanced stages of chronic heart failure
has not been systematically investigated.
METHODS
In this prospective, single-center study, we included
consecutive patients undergoing TMVR with the
MitraClip system. All patients underwent close clin-
ical follow-up (FU) and echocardiography after
6 months to determine functional results after TMVR
and clinical outcomes.
PATIENTS. Symptomatic patients with relevant DMR
grade 3 to 4þ were evaluated for TMVR or surgery.
Patients with FMR and mitral regurgitation grade 2þ
were considered for MR treatment when having an
effective regurgitation oriﬁce area of >20 mm2,
New York Heart Association (NYHA) functional
class III to IV, concomitant atrial ﬁbrillation, and/orelevated pulmonary pressure despite opti-
mized medical and device therapy (8). TMVR
was planned for patients if the heart team
recommended against open-heart surgery.
The study was approved by local ethics
committee and in concordance with the
Declaration of Helsinki, and all patients had
to provide written informed consent before
study inclusion.
ECHOCARDIOGRAPHY AND FU ASSESSMENT.
Echocardiographic assessment before and
after TMVR was done following current rec-
ommendations and guidelines, including
comprehensive transthoracic echocardiogra-
phy (TTE) and transesophageal echocardiog-
raphy (TEE) (9,10). Severity of MR was graded
after determination of proximal isovelocity
surface area, effective regurgitation oriﬁce area, as
well as vena contracta width and regurgitant volume
(8,9). According to the EVEREST (Endovascular Valve
Edge-to-Edge REpair Study) (7) and the recommen-
dations of the European Society of Cardiology (9), we
established an institutional standard categorizing the
severity of MR following a scale ranging between 1
and 4þ: grade 1 deﬁnes “mild,” 2 refers to “moder-
ate,” 3 stands for “moderate to severe,” and 4 stands
for “severe” MR. TEE and TTE were performed with
a commercially-available echocardiographic system
(iE 33, Philips Medical Systems, Andover, Massachu-
setts) and echocardiography probes (X5-1, X7-2t)
allowing acquisition of 2- and 3-dimensional data-
sets. For the determination of iASD during FU, the
interatrial septum was visualized in multiple angu-
lations with and without color Doppler to identify
visible structural defect or atypical interatrial
Doppler ﬂow (Figure 1).
Different experienced echocardiographers ob-
tained procedural (C.H., F.S.) and FU (R.S., C.Ö.)
images. The echocardiographer who performed FU
evaluation was blinded to procedural outcomes and
the patients’ characteristics. Trained study nurses
carried out clinical FU evaluation, unattended by the
interventionalists or procedural echocardiographer.
INTERVENTIONAL EDGE-TO-EDGE REPAIR OF MR.
TMVR using the MitraClip system has been described
in detail previously (7). During the MitraClip proce-
dure, severity and acute changes of MR were assessed
as supposed by Foster et al. (11) and Wunderlich and
Siegel (12). We deﬁned acute procedural success as a
reduction of MR by at least 1 grade, with a residual
MR <2þ. The number of clips that were implanted to
reach procedural success was left to the discretion of
FIGURE 1 Examples of Spontaneous iASD Closure and Persistent iASD 6 Months After MitraClip Treatment
(A to C) Spontaneous iatrogenic atrial septal defect (iASD) closure. (D to F) Persistent iASD. (A and D) No interatrial shunt defect detectable
with color Doppler prior to transseptal puncture in both cases. (B and E) iASD immediately after MitraClip implantation with left-to-right
shunting. (C) Spontaneous iASD closure 6 months after MitraClip implantation. (F) Persistent iASD at 6-month follow-up (FU), with new right-
to-left shunt and interatrial septum deviation. This patient presented increasing systolic pulmonary arterial pressure of 70 mm Hg and
increasing levels of N-terminal pro-brain natriuretic peptide.
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452the treating physician. Before clip release, echocar-
diography was performed to exclude clinical relevant
MV stenosis (mean pressure gradient >5 mm Hg).
Clinical success was deﬁned by a decrease of $1
NYHA functional class during FU.
STATISTICAL ANALYSIS. Normal distribution of
continuous variables was examined using the
Kolmogorov-Smirnov test. Comparisons between
FMR and DMR groups at 6 months were done using
analysis of covariance for continuous variables.
Further comparisons were performed with using the
Student 2-sample t test or Mann-Whitney U test
depending on the distribution of data. For categorical
data, the Fisher exact test or chi-square test was
calculated. Continuous data were expressed as mean
 SD or median (with interquartile ranges) where
applicable. The 2-tailed p values were calculated, andp < 0.05 was considered to be signiﬁcant. The cu-
mulative survival plot in relation to iASD was esti-
mated by the Kaplan-Meier method. Survival in
groups was compared using the log-rank test. Cox
regression was performed to analyze the inﬂuence of
single variables on 6-month mortality. Variables were
chosen for Cox regression if they have been shown
independently to increase heart failure–related mor-
tality in MR patients. Due to the relatively low event
rate at 6-month FU, multivariate analysis was not
performed.
Intraclass correlation coefﬁcients for absolute
agreement was used to assess method agreement,
with good agreement deﬁned as >0.80. For the
assessment of intraobserver reliability, 20 randomly-
chosen patients from each group (iASD and no iASD)
were analyzed by the same investigator twice (C.H.),
then by a second investigator (R.S.) who was blinded
TABLE 1 Baseline Characteristics Separated by iASD Persistence
All Patients
(n ¼ 66)
iASD
(n ¼ 33)
no iASD
(n ¼ 33) p Value
Age, yrs 77.1  7.9 76.6  8 77.7  8 0.6
Female 15 (23.3) 7 (21) 8 (24) 0.7
Body mass index, kg/m2 26.2  4.2 26.3  4.2 26.1  4.2 0.8
EuroSCORE II, % 10.1  6.1 11  7.2 9.2  4.6 0.2
Functional MR 48 (73) 24 (73) 24 (73) 1
AF 46 (70) 26 (79) 21 (62) 0.2
History of cardiac decompensation 39 (65) 18 (60) 21 (70) 0.3
Coronary heart disease 40 (60) 22 (67) 18 (55) 0.3
Diabetes mellitus 18 (27) 11 (33) 7 (21) 0.1
AHT 47 (72) 23 (70) 24 (73) 0.5
Smoking 24 (37) 13 (39) 11 (33) 0.4
Hyperlipidemy 28 (42) 15 (45) 13 (39) 0.3
Stroke 3 (5) 1 (3) 2 (6) 0.5
NYHA functional class 3.3  0.5 3.2  0.5 3.3  0.5 0.6
Values are mean  SD or n (%).
AF ¼ atrial ﬁbrillation; AHT ¼ arterial hypertension; iASD ¼ iatrogenic atrial septal defect; MR ¼ mitral
regurgitation; NHYA ¼ New York Heart Association functional class, 6MWD ¼ 6-min walking distance.
TABLE 2 Procedural Details and Outcomes
All Patients iASD No iASD p Value
Procedure time, min 75.8  42.8 82.4  39.7 68.9  45.5 0.05
Radiation time, min 24.5  17.7 30.5  20.6 18.6  11.9 0.05
Number of clips 0.4
1 clip 40 (60) 19 (58) 21 (64)
$2 clips 26 (40) 14 (42) 12 (36)
Procedural success 65 (98) 33 (100) 32 (97) 0.5
Repeated procedure 7 (10) 3 (9) 4 (12) 0.6
Surgery 0 0 (0) 0 (0) —
Endovascular 7 (10) 3 (9) 4 (12) 0.6
Hospital death 0 0 (0) 0 (0) —
Intraprocedural death 0 0 (0) 0 (0) —
MACCE 0 0 (0) 0 (0) —
Stroke 0 0 (0) 0 (0) —
Minor bleeding 7 (10) 0 (0) 7 (21) 0.03
Transfusion/major bleeding
requiring transfusion
5 (7) 0 (0) 5 (15) 0.02
Major vascular complications 0 0 (0) 0 (0) —
30-day mortality 2 (3) 2 (6) 0 (0) 0.3
6-month mortality 7 (11) 6 (18) 1 (3) 0.04
Values are mean  SD or n (%). Bold p values indicate statistically signiﬁcant results.
iASD ¼ iatrogenic atrial septal defect; MACCE ¼ major adverse cardiac and cerebrovascular events
(combined endpoint for cardiac events and mortality).
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453to the results of the ﬁrst investigator, to determine
interobserver variability. Mean values and SDs be-
tween the measurements were obtained, and absolute
agreement among the observations was calculated
using intraclass correlation coefﬁcient analysis.
Statistics were performed using the SPSS for Win-
dows PASW statistic, version 20.0.0.0 (SPSS Inc.,
Chicago, Illinois) and MedCalc statistical software
version 11.4.1.0 (MedCalc, Mariakerke, Belgium).
RESULTS
BASELINE DATA AND PROCEDURAL OUTCOMES.
From February to December 2013, 66 consecutive
patients (age 77.1  7.9 years, 76.7% male, EuroSCORE
II 10.1  6.1%, 73.3% FMR) (Table 1) underwent TMVR
with the MitraClip system at our institution and
completed the 6-month FU procedure including TTE
and TEE. The patients underwent MitraClip pro-
cedures primarily for the treatment of advanced
stages of symptomatic heart failure, with 96.7% of
patients in NYHA functional class III or IV and 51% of
patients with documented left ventricular ejection
fraction (LVEF) <35%. The procedure was success-
fully completed in 65 patients (98.5%), with implan-
tation of >1 clip in 40% of cases. Mean procedural
time was 75.8  42.8 min (interquartile range: 26 to
221 min) with a documented ﬂuoroscopy time of
24.5  17.7 min (interquartile range: 5 to 100 min)
(Table 2). In 1 patient, TMVR was aborted because of
relevant MV stenosis occurring after clip closure;
in this case, the system was retrieved uneventfully
without post-procedure changes in MR. Thereafter,
the patient was treated conservatively, because of
prohibitive surgical risk.
In-hospital, 30-day, and 6-month outcomes are
shown in Table 2. The majority of patients improved
signiﬁcantly after FU, with documented decrease
of $1 NYHA functional class in 81.6% of cases.
ECHOCARDIOGRAPHIC MEASURES AFTER FU. Echo-
cardiography after 6 months revealed sustained
reduction of MR <2þ in 91.6% of patients (Figure 2A).
Concomitantly, we found a signiﬁcant reduction in
estimated systolic pulmonary arterial pressure (sPAP)
(43.6  14.1 mm Hg vs. 35.6  16.6 mm Hg; p ¼ 0.02)
and left ventricular (LV) end-diastolic volume
(195.1  77.2 ml vs. 176.9  84.7 ml; p ¼ 0.03) in the
overall cohort, without signiﬁcant changes in LV
end-systolic volume (121.7  69.4 ml vs. 109.8 
73.3 ml; p ¼ 0.1) or LVEF (41.2  15.8% vs. 42.3 
14.5%; p ¼ 0.7).
Mean MV pressure gradients were signiﬁcantly
increased after MitraClip procedures (1.5  0.8 mm Hgvs. 3.4  1.5 mm Hg; p ¼ 0.001) without incidence of
signiﬁcant MV stenosis (Online Table 1).
PERSISTENCE OF IASD AND COMPARISON OF
BASELINE CHARACTERISTICS. Persistence rate of
iASD as documented with TEE was 50%, with
measured maximal and minimal diameters of 4.3 
1.7 mm (interquartile range: 1.1 to 7.9 mm) and 3.8 
2.1 mm (interquartile range: 1.2 to 7.1 mm), respec-
tively. In 2 of 33 cases (6%), TEE showed
FIGURE 2 Stapled Columns of MR Grading and NYHA Functional Classes Before and 6 Months After TMVR Procedures
(A) Mitral regurgitation (MR) grading; (B) New York Heart Association (NYHA) functional classes. ASD ¼ atrial septal defect; iASD ¼ iatrogenic
atrial septal defect.
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454spontaneous right-to-left shunt via iASD. When
comparing groups separated by persistence of iASD
after 6 months, we found no signiﬁcant differences
concerning baseline characteristics (Table 1), acute
procedural success rates, MV gradient, and amount
of residual MR after clip placement (Table 2). TMVRtook longer in patients with iASD (82.4  39.7 min vs.
68.9  45.5 min; p ¼ 0.05), which was associated with
longer radiation times (30.5  20.6 min vs. 18.6 
11.9 min; p ¼ 0.05).
We found no signiﬁcant differences between
groups in baseline functional parameters, severity of
TABLE 3 Baseline Echocardiographic Measures of Patients Separated by
Persistence of iASD
All Patients iASD No iASD p Value
LVEF, % 41.2  15.8 40.4  14.9 42.1  16.9 0.6
LVVd, ml 195.1  77.2 191.6  75.3 198.4  80.2 0.7
LVVs, ml 121.7  69.4 120.7  65.6 122.7  74.1 0.9
LVEDD, cm 6.7  0.9 7.3  0.7 6.1  0.7 0.08
LVESD, cm 5.1  1.3 5.7  1.4 4.5  0.9 0.07
LAvol, ml 154.8  65.2 162.5  63.3 147.5  67.4 0.4
EROA, cm2 0.5  0.2 0.4  0.2 0.5  0.3 0.1
Reg. volume, ml 48.8  18.1 46.4  14.7 51.2  21 0.3
PISA 0.8  0.2 0.8  0.2 0.8  0.1 0.8
Vena contracta, cm 0.9  1.6 0.7  0.2 1.1  2.2 0.3
MR grade 3  0.4 3  0.4 3  0.4 1
I 0 0 (0) 0 (0)
II 0 (0) 0 (0) 0 (0)
>II 66 (100) 33 (100) 33 (100) 1
MV gradient 1.5  0.8 1.7  0.8 1.3  0.7 0.08
RVD1, cm 4.8  0.8 5.1  0.8 4.6  0.8 0.01
RVD2, cm 3.5  0.8 3.7  0.8 3.3  0.7 0.03
RVD3, cm 8.3  1 8.4  1.0 8.1  0.9 0.2
TAPSE, cm 1.8  0.5 1.8  0.5 1.8  0.5 1
sPAP, mm Hg 42.9  13.9 42.5  13 43.4  15.1 0.8
TR grade
I 14 (21) 8 (24) 6 (18)
II 25 (38) 14 (42) 11 (33)
>II 27 (40) 12 (36) 15 (45) 0.3
RAarea, cm
2 26.9  8.3 28.8  7.4 24.9  8.9 0.09
Values are mean  SD or n (%). Bold p values indicate statistically signiﬁcant results.
EROA ¼ effective regurgitant oriﬁce area; LAvol ¼ left atrial volume; LVEDD ¼ left ventricular
end-diastolic diameter; LVESD ¼ left ventricular end-systolic diameter; LVEF ¼ left ventricular
ejection fraction; LVVd ¼ left ventricular volume during diastole; LVVs ¼ left ventricular volume
during systole; PISA ¼ proximal isovelocity surface area; RA ¼ right atrium; Reg. ¼ regurgitation;
RVD ¼ right ventricle diameter; sPAP ¼ right ventricular systolic pressure; TAPSE ¼ tricuspid
annular plane systolic excursion; TR ¼ tricuspidal regurgitation; other abbreviations as in Table 1.
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 3 , 2 0 1 5 Schueler et al.
M A R C H 2 0 1 5 : 4 5 0 – 9 Persistence of Iatrogenic ASD After MitraClip
455MR, or measured sPAP. Patients with persistent iASD
had larger basal (5.1  0.8 cm vs. 4.6  0.8 cm; p ¼
0.01) and midventricular (3.7  0.8 cm vs. 3.3  0.7
cm; p ¼ 0.03) right ventricular diameters at baseline
(Table 3).
ASSOCIATION OF IASD WITH ECHOCARDIO-
GRAPHIC MEASURES AFTER FU. When separating
patients according to presence of iASD after
6 months, we found no signiﬁcant differences in
residual MR, MV gradients, or LV diastolic volume
and function. In concordance with the obtained
baseline measurements, right ventricular diameters
remained larger in iASD patients but did not
signiﬁcantly differ from baseline (Online Table 1).
Interestingly, only patients without iASD experi-
enced signiﬁcant reductions in LV end-diastolic
(198.4  80.2 ml vs. 174.4  94.1 ml; p ¼ 0.04) and
end-systolic (122.7  74.1 ml vs. 103.9  79.3 ml; p ¼
0.05) volumes during FU, without signiﬁcant changes
in measured LV function (LVEF: 42.1  16.9% vs. 44.9
 14.7%; p ¼ 0.3) (Table 4).
The decrease in echocardiographically-measured
sPAP was signiﬁcantly different between groups
(Figure 3A); only patients without iASD experienced
a signiﬁcant decrease of measured sPAP (43.47 
15.1 mm Hg vs. 32.5  11.9 mm Hg; p ¼ 0.03),
whereas sPAP remained unchanged in the iASD
group (42.5  13 mm Hg vs. 44.1  19.2 mm Hg;
p ¼ 0.8) (Online Table 1). Furthermore, right atrial
areas increased signiﬁcantly in the iASD group dur-
ing FU (28.9  7.4 cm2 vs. 34.2  11.7 cm2; p ¼
0.002) with a concomitant decrease in left atrial
volumes (162.5  63.3 ml vs. 139.1  47.6 ml; p ¼
0.04) (Table 4). In patients without ASD, there were
no signiﬁcant changes in right and left atrial di-
mensions (p > 0.05).
ASSOCIATION OF IASD WITH FUNCTIONAL OUT-
COMES AND SURVIVAL. Patients with iASD experi-
enced a signiﬁcantly lower increase in 6-min walking
distances compared with patients without iASD (20.8
 107.4 m vs. 114.6  116.4 m; p ¼ 0.001) (Figure 3B)
and showed higher levels of N-terminal pro-brain
natriuretic peptide 6 months after clip placement
(6,667.3  7363.9 ng/dl vs. 4,835.9  6,681.7 ng/dl;
p ¼ 0.05).
Overall, 57% of patients with iASD remained in
functional NYHA functional class >II compared with
30% of patients without iASD (p ¼ 0.04) (Figure 2B).
Survival rates were signiﬁcantly different between
groups: 6 patients (16.6%) with iASD died during FU
compared with 1 patient (3.3%) in the groups without
iASD (log rank p ¼ 0.05) (Figure 4).After Cox regression analysis, only the presence of
iASD was associated with survival during FU (Table 5).
The echocardiographic FU evaluation had a good
reproducibility. We found a good intraclass and
interclass absolute agreement, with all correlation
coefﬁcients ranging above 0.8 (Table 6).
DISCUSSION
To our knowledge, this is the ﬁrst study investigating
the persistence rates of iASD after interventional
edge-to-edge repair with serial TEE examinations and
close clinical FU. Following our results, the persis-
tence rate of iASD after MitraClip procedures with
transseptal left atrial access was high (50%). This
ﬁnding is clinically important because persistent
interatrial shunt was associated with worse hemo-
dynamic and clinical development after TMVR and—
more importantly—with an increased probability for
all-cause death.
TABLE 4 Echocardiographic Assessment of Patients Before and
After Follow-Up
iASD No iASD p Value
LVVd, ml
Baseline 191.7  75.29 198.4  80.2 0.7
Follow-up 179.6  75.1 174.4  94.1 0.8
p value 0.6 0.04
LVVs, ml
Baseline 120.7  65.6 122.7  74.1 0.9
Follow-up 116.1  67.2 103.9  79.3 0.5
p value 0.8 0.06
LAvol, ml
Baseline 162.5  63.3 147.5  67.5 0.4
Follow-up 139.1  47.6 147.3  60.9 0.6
p value 0.04 0.9
MR >II
Baseline 33 (100) 33 (100) 1
Follow-up 4 (13) 1 (3.3) 0.7
p value <0.0001 <0.0001
MV gradient
Baseline 1.7  0.8 1.3  0.7 0.08
Follow-up 3.1  1.1 3.7  1.9 0.4
p value <0.0001 <0.0001
sPAP, mm Hg
Baseline 42.5  13 43.4  15.1 0.8
Follow-up 44.1  19.2 32.5  11.9 0.03
p value 0.2 0.03
RVD2, cm
Baseline 3.7  0.8 3.3  0.7 0.03
Follow-up 3.9  0.9 3.3  0.9 0.04
p value 0.2 0.8
RA area, cm2
Baseline 28.8  7.4 24.9  8.9 0.09
Follow-up 34.2  11.7 24.3  6.2 0.001
p value 0.002 0.7
Values are mean  SD or n (%). Bold p values indicate statistically signiﬁcant
results.
MV ¼ mitral valve; other abbreviations as in Table 3.
Schueler et al. J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 8 , N O . 3 , 2 0 1 5
Persistence of Iatrogenic ASD After MitraClip M A R C H 2 0 1 5 : 4 5 0 – 9
456The reasons for these unfavorable outcomes
remain unclear at the current stage. As a matter of
fact, at-risk patients need special care, because the
hemodynamic effects of interatrial shunt defects in
patients with predominantly advanced stages of
chronic heart failure have not been systematically
investigated.
PERSISTENCE RATES OF IASD AFTER CARDIAC
INTERVENTIONS WITH TRANSSEPTAL ACCESS.
Limited data are available on persistence rates and
predictors for iASD after different cardiac procedures.
According to our own experiences, the underlying
pathomechanism combines technical, interventional,
and patient-derived factors. We investigated 42 pa-
tients undergoing pulmonary vein isolation with
either single (n ¼ 27) or double (n ¼ 15) transseptal 8-F
catheters. Factors associated with iASD persistenceafter FU were the use of a single transseptal sheath
demanding more extensive interatrial movement (p ¼
0.01) and the prevalence of pulmonary hypertension
before pulmonary vein isolation (p ¼ 0.05) (13). More
recently, Sieira et al. (14) described a 12-month
persistence rate of 20% for iASD in 39 patients un-
dergoing pulmonary vein isolation with considerably
larger 15-F transseptal sheaths.
When regarding other structural/transseptal in-
terventions, iASD persisted in 18% of patients un-
dergoing mitral valvuloplasty with dilation of the
interatrial septum by using an 8-mm balloon (15) and
in 7% of patients after left atrial appendage closure
with a 12-F transseptal sheath (16).
At this time, only 1 study has investigated persis-
tence rates for iASD after MitraClip implantations
with TEE. Saitoh et al. (17) examined 10 patients
1 month after MitraClip implantation and found a
90% iASD persistence rate. In our study, iASD
persistence was considerably less, which can be
explained by the fact that the FU period was rele-
vantly longer, allowing for further defect healing. We
did not compare intraprocedural iASD diameters of
patients separated by iASD persistence.
When putting our ﬁndings in context with the
available evidence, the iASD persistence rate of 50%
seems caused by predominantly 2 factors: 1) TMVR
with the MitraClip requires extensive movement of a
large transseptal sheath (21-F, 7.3 mm); and 2) local
trauma increases with rising procedural time in the
iASD group.
CLINICAL EFFECT OF INTERATRIAL SHUNT DEFECTS
IN A “MITRACLIP POPULATION”. Available evidence
is sparse investigating hemodynamic effects and
clinical consequences of iASD after TMVR with the
MitraClip systems. Theoretically, iASD with bidirec-
tional interatrial shunt can provoke paradoxical em-
bolism and worsen clinical symptoms of heart failure
due to volume overload. However, Hoffman et al. (18)
found evidence for beneﬁcial hemodynamic conse-
quences of iASD in 28 patients undergoing MitraClip
procedures caused by acute left atrial pressure relief.
Our ﬁndings on reverse changes of right and left atrial
dimensions in patients with iASD support this hy-
pothesis. However, according to the clinical outcomes
in our cohort after 6 months, persistent right atrial
volume overload seems to not be beneﬁcial in this
patient group.
Conversely, several case reports have been pub-
lished describing detrimental clinical effects of iASDs
in selected patients with predominantly advanced
stages of chronic heart failure. In all cases, symptoms
abated after interventional iASD closure, supporting
FIGURE 3 Improvement in Measured sPAP and 6MWT After FU
(A) Measured systolic pulmonary arterial pressure (sPAP); (B) 6-min walk test (6MWT). Abbreviations as in Figure 2.
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457the hypothesis of the iASD being the underlying cause
of disease (19,20). Sirker et al. (20) found increased
oxygen requirements in a patient with persistent
iASD after transseptal MV surgery; the patient
improved immediately after iASD device closure.
Huntgeburth et al. (19) found worsening of right-
heart failure related symptoms in 3 patients after
MitraClip procedures, and all patients were treated
successfully with interventional defect closure (19).
When adding these ﬁndings with the available
evidence on procedural shunt defects, a negative
hemodynamic or clinical effect of iASD was never
shown in larger cohorts of patients undergoing pul-
monary vein isolation (14,21), mitral valvuloplasty
(22) or LAA closure (16).FIGURE 4 Kaplan-Meier Curves for Survival After 6 Months
iASD ¼ iatrogenic atrial septal defect.What makes the d i f ference in MitraC l ip
pat ients? First, MitraClip therapy is primarily per-
formed in selected high-risk patients who receive
TMVR for the treatment of advanced stages of symp-
tomatic chronic heart failure accompanied by reduced
LV function and increased LV end-diastolic pressures
(6,23–25). Second, the atrial defect size after TMVR is
considerably larger (17), increasing interatrial shunt
volumes. Third, persistence rates are high due to
extensive movement of a large sheath during complex
procedures. The acute and persistent hemodynamic
effects of interatrial shunting in this vulnerable pop-
ulation have not yet been investigated. In line with an
increasing number of published case reports in this
ﬁeld, there is growing evidence that iASD might
negatively affect clinical patient outcomes.
STUDY LIMITATIONS. We investigated only a small
number of patients who underwent TMVR pro-
cedures with the MitraClip system, and other groups
should conﬁrm our ﬁndings independently. Ideally,TABLE 5 Cox Regression Analysis of Factors Predicting
6-Month Mortality
HR 95% CI p Value
iASD 6.4 1.0–23.4 0.04
Creatininebaseline, mg/dl 1.8 1.1–3.0 0.07
NT-proBNPbaseline, ng/dl 1.0 1.0–1.0 0.4
Age, yrs 1.0 0.9–1.1 0.7
LVEF, % 1.0 0.9–1.1 0.8
FMR 0.9 0.2–4.7 0.9
sPAP, mm Hg 1.0 0.9–1.0 0.4
Severe TI 1.1 1.0–1.4 0.4
Bold p values indicate statistically signiﬁcant results.
CI ¼ conﬁdence interval; FMR ¼ functional mitral regurgitation; HR ¼ hazard
ratio; NT-proBNP ¼ N-terminal pro-brain natriuretic peptide; TI ¼ tricuspid valve
insufﬁciency; other abbreviations as in Tables 1 and 3.
TABLE 6 Intraclass Correlations for Intraobserver and
Interobserver Agreement of Echocardiographic Follow-Up
Parameters
Interobserver
Agreement p Value
Intraobserver
Agreement p Value
LVEF 0.89 0.004 0.93 <0.001
sPAP 0.88 0.005 0.92 <0.001
TAPSE 0.90 0.002 0.91 <0.001
LVVS 0.91 0.002 0.95 <0.001
LVVD 0.87 0.007 0.91 0.002
LAvol 0.90 0.002 0.92 <0.001
RA area 0.92 0.003 0.91 <0.001
RVD1 0.88 0.004 0.89 0.005
RVD2 0.89 0.003 0.91 <0.001
Abbreviations as in Table 3.
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458the hemodynamic effects of interatrial shunt defects
would be determined invasively at baseline and
during FU. At this stage, it remains unclear whether
iASD is the reason for or effect of unfavorable he-
modynamic and clinical outcome measures. We
report the ﬁndings of a single-center study and
cannot exclude that procedural details and inter-
ventional steps differ signiﬁcantly from other sites,
which might have a relevant effect on iASDpersistence rates. We, furthermore, cannot exclude a
documentation bias of clinical outcome measures,
because statistical testing for reliability was not per-
formed. However, in every patient, clinical assess-
ment was performed by trained nurses, and the
plausibility of the results was checked by experi-
enced physicians. Additionally, clinical measures
were correlated with quantitative parameters on
functional capacity (N-terminal pro-brain natriuretic
peptide, 6-min walk distance).
CONCLUSIONS
The iASD persistence rate of 50% after MitraClip
procedures is considerably high. Persistence of
interatrial shunting was associated with worse clin-
ical outcomes and increased mortality rates. Further
studies are warranted to investigate if iASD is a
mediator or marker for advanced stages of chronic
heart disease in these patients.
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